Johnson & Johnson Announces Orthopedics Spin-off, Gan & Lee Appoints New Executive, and Mindray Files for Hong Kong Listing

Oct 16, 2025 19:40 CST Updated 19:40

Johnson & Johnson

Medical Device R&D and Manufacturer

Legend Biotech

Tumor Cell Immunotherapy Developer

Gan&Lee Pharmaceuticals

Biological Synthetic Human Insulin Pharmaceutical R&D Manufacturer

DePuy Synthes

Orthopedic Product Developer

Johnson & Johnson Plans to Spin Off DePuy Synthes

10Month14DayEvening, Johnson & Johnson announced2025YearThe Third QuarterFinancial Report：Revenue reached240billion dollars, a year-on-year increase of6.8%。As of the third quarter of this year, Johnson & Johnson'sTotal revenue has reached696.29Billion USD`, year-on-year growth`5%, including innovative pharmaceuticals and medical technologyContributed by the two major business segmentsRevenueRespectively reaching446.38Billion USD (+4.7%) and236.69Billion USD (+5.6%）。

Specifically,Johnson & Johnson's innovative pharmaceutical business mainlyFocus on Oncology, Autoimmunity, Neuroscience, Pulmonary Hypertension, Infectious Diseases, Cardiovascular and Metabolic DisordersThisSix Major Sectors，The first nine months generated revenue respectively185.19Billion USD (+21.2%）、118.68Billion USD (-12.7%）、57.22Billion USD (+7.2%）、32.53Billion USD (+2%）、24.34Billion USD (-7.2%）、28.42Billion USD (+9.1%）。

Among them, Johnson & Johnson's oncology business performed remarkably, particularly its collaboration with Legend Biotech in co-development.BCMA CAR-TProductCarvykti(Cilta-cel) achieved revenue in the first nine months13.32billion dollars, compared to the same period last year6.29Achieved a doubling of growth in billions of dollars.

It is worth mentioning that,On the same day of announcing its earnings, Johnson & Johnson also announced plans for the future.18To24The decision to spin off the orthopedics business and establish an independent company within months. It is reported that,Splitting the companyByNamed asDePuy Synthes, andNamal NawanaWill assume the position of its Global President.

According to Johnson & JohnsonIntroduction, whose orthopedic business in2024Annual income is approximately92Billion USD，ExpectedDePuy SynthesWillBecomeThe world's largest company focused on the orthopedic field, it will occupy a leading market position in major product categories (such as hip, knee, and shoulder implants, as well as surgical instruments).

Former Novo Nordisk Executive Joins Gan&Lee Pharmaceuticals

10Month14On (date), Gan&Lee Pharmaceuticals announced the appointment of Ting Jia as Vice President and Chief Medical Officer (Corporate Vice President & Chief Medical Officer). Jia Ting will be fully responsible for the clinical development, registration strategy, and cross-team collaborative management of the company's products under research in the European and American regions, aiming to accelerate the global market launch process of Gan&Lee Pharmaceuticals' innovative drugs and commit to providing breakthrough treatment solutions for patients worldwide.

Jia Ting graduated from Karolinska Institutet in Sweden.GetA medical doctorate degree and completed postdoctoral research. She has over15With years of profound scientific research and global clinical development experience, focusing on diabetes, obesity, kidney diseases, and other chronic metabolic disorders, combining an outstanding academic background with extensive multinational project management capabilities.

Before joining Gan&Lee Pharmaceuticals, Jia Ting worked at Novo Nordisk, overseeing the full lifecycle management of multiple innovative drugs. She was responsible for formulating clinical strategies, designing and executing trial protocols, and successfully driving the approval and indication expansion of several products in major markets such as the United States, Europe, and China.

Mindray Medical Goes Public in Hong Kong

10Month14On the evening of the day, Mindray Medical announced that after full research and deliberation, the company plans to issueHShares and listed on the Main Board of the Hong Kong Stock Exchange.At the same time,Announced on the same dayRecord of Investor Relations ActivitiesChinaAlsoResponded to the purpose and necessity of listing in Hong Kong,ItsThe company firmly believes that this offshore issuance and listing is a steadfast implementation of its strategy."Internationalization" strategy's important measure.

Mindray Medical stated that it has now become a globalTop30Medical device companies with multiple product lines ranking among the top three globally in terms of market share, and with nearly half of their revenue coming from international business, have established a solid foundation for global operations. This application for listing on the Hong Kong stock exchange will deeply promote the strategic synergy of "business globalization" and "capital globalization": On one hand, it will help the company more efficiently connect with overseas market resources, further enhancing its global influence, and provide strong capital support for competing with international giants in the global market; on the other hand, by leveraging the international influence of the Hong Kong market, it will communicate to global investors the company's positioning and investment value as a "globally leading, innovation-driven world-class medical device enterprise and leader in digital and intelligent healthcare," significantly improving the company's brand recognition and influence in the international capital markets and the global medical device industry.

Editor: Li Yongshi

Layout Editor: Yu Yuanze

Reviewed by: Ma Fei, Zhang Song